MARSHALL & POPP, LLC

Lobbying for BRIDGEBIO PHARMA · Biopharmaceutical manufacturer.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $60,000.00 income · posted Jan 16, 2026

Lobbying activity 1

Pharmacy

Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.